

[Gemcitabine](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01BC05](#)

Indication

Other specified carcinomas of ovary ICD11 code: [2D23.0Y](#)

INN

Gemcitabine

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 200 mg in vial powder for injection ; 1 g in vial powder for injection

EML status history

First added in 2015 ([TRS 994](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Gemcitabine](#)

[DrugBank](#)

[Gemcitabine](#)

Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, gemcitabine was added to the complementary list of the EML for use in treatment protocols for epithelial ovarian cancer. The relevant extract from TRS994 regarding the Expert Committee's consideration of treatment protocols for epithelial ovarian cancer is attached.